Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Fineline Cube Jun 25, 2026
Company Deals

YHLO Biotech and Jingyi Bio Forge Strategic Alliance to Advance Neuroimmunology Diagnostics – Expanding Autoimmune Testing into Neurological Disorders

Fineline Cube Jun 24, 2026
Company Deals

Fusen Pharmaceutical Secures RMB 300M Strategic Investment for Henan Subsidiary Debt Restructuring and Working Capital

Fineline Cube Jun 24, 2026
Company Deals

AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline

Fineline Cube Jun 24, 2026
Company Deals

BioArctic Partners with Eli Lilly on Novel Neurodegenerative Disease Therapy Using BrainTransporter Platform

Fineline Cube Jun 23, 2026
Policy / Regulatory

China Launches 12th National Drug Volume-Based Procurement Batch with 65 Products, Patent Disputes Highlighted

Fineline Cube Jun 24, 2026
Company Drug

Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP

Fineline Cube Jun 25, 2026
Company Drug

Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients

Fineline Cube Jun 25, 2026
Drug Policy / Regulatory

CDE Releases 67th Batch of Chemical Generic Reference Preparations

Fineline Cube Feb 22, 2023

The Center for Drug Evaluation (CDE) has released the 67th batch of chemical generic reference...

Drug

CDE Releases Guidelines for Chemically Synthesized Peptide Research

Fineline Cube Feb 22, 2023

The Center for Drug Evaluation (CDE) has released the “Technical Guidelines for Pharmaceutical Research of...

Company Drug

Junshi Biosciences’ PD-1 Inhibitor Tuoyi Shows Promise in Phase III TNBC Study

Fineline Cube Feb 21, 2023

Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced significant progress in the Phase...

Company Deals

Abbott Partners with Sinopharm for Expanded Medical Solutions in China

Fineline Cube Feb 21, 2023

US-based Abbott (NYSE: ABT) has entered into a strategic partnership with Sinopharm’s China National Medical...

Company Drug

Luoxin’s Tegoprazan Gains NMPA Review for Duodenal Ulcer Treatment

Fineline Cube Feb 21, 2023

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793), a leading China-based pharmaceutical company, has...

Company Drug

Shanghai Pharmaceuticals’ X842 Accepted for NMPA Review for Reflux Esophagitis

Fineline Cube Feb 21, 2023

China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has announced that the National Medical Products...

Company Deals Medical Device

We-Linking Raises Tens of Millions in Angel Round for Brain-Computer Interface

Fineline Cube Feb 21, 2023

We-Linking, a developer of fully implantable wireless brain-computer interface systems based in Shenzhen, has reportedly...

Company Deals

Hybio Pharma and CR Medicine Collaborate on Market Expansion

Fineline Cube Feb 21, 2023

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has entered into a collaboration agreement with compatriot...

Company Drug

Junshi Biosciences Seeks UK MHRA Approval for PD-1 Inhibitor Tuoyi

Fineline Cube Feb 21, 2023

Junshi Biosciences (HKG: 1877, SHA: 688180), a leading China-based biotech firm, has announced the submission...

Company Drug

Chinagene Tech Initiates ZVS101e Gene Therapy Trial for Bietti’s Crystalline Dystrophy

Fineline Cube Feb 21, 2023

Beijing-based Chinagene Tech, a specialist in hereditary ophthalmopathy diagnosis and gene therapy, has announced the...

Company Drug

Ascletis Pharma’s ASC10 Shows Promising Phase I Results at CROI 2023

Fineline Cube Feb 21, 2023

China-based Ascletis Pharma Inc. (HKG: 1672) has announced positive results from a Phase I clinical...

Company Deals

Beijing Huashen Shengdian Secures Angel Funding for Pelvic Surgery Monitor R&D

Fineline Cube Feb 21, 2023

China-based intraoperative nerve monitoring technology developer Beijing Huashen Shengdian Medical Technology Co., Ltd has reportedly...

Company Drug

Zhaoke’s Generic Bimatoprost + Timolol Maleate Eye Drops Approved in China

Fineline Cube Feb 21, 2023

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) former subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) has announced...

Company Drug

Sino Biopharmaceutical’s Limaprost Approved by NMPA for Lumbar Spinal Stenosis Treatment

Fineline Cube Feb 21, 2023

Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received marketing approval from China’s...

Company R&D

Biocytogen’s ‘Nano 100 Project’ Aims to Develop Over 100 Fully Human Nanobody Drugs

Fineline Cube Feb 21, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced the launch of the “Nano 100 Project,”...

Company Deals

Suzhou Porton Biologics Partners with Yinjia Biosciences for CGT Development

Fineline Cube Feb 21, 2023

China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has struck a partnership...

Company Drug

Biosyngen’s BRG01 Gets FDA Nod for NPC Clinical Study

Fineline Cube Feb 20, 2023

Cell and gene therapy (CGT) specialist Biosyngen Pte Ltd has announced receiving approval from the...

Policy / Regulatory

CDE Issues Guidelines for Real-World Drug Research and Evidence Framework

Fineline Cube Feb 20, 2023

The Center for Drug Evaluation (CDE) has released two important documents: the “Guiding Principles of...

Company Policy / Regulatory

China’s 8th Volume-Based Procurement Round Begins Drug Info Filing

Fineline Cube Feb 20, 2023

The national drug alliance procurement office has released a notification initiating the drug information filing...

Company Drug

BRL Medicine Achieves First Cure of Thalassemia Major with BRL-101

Fineline Cube Feb 20, 2023

Shanghai-based BRL Medicine Inc. has announced a significant breakthrough in the treatment of thalassemia major....

Posts pagination

1 … 582 583 584 … 687

Recent updates

  • Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster
  • Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP
  • Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients
  • Henlius and Organon Canada Launch Denosumab Biosimilars BILDYOS and TUZEMTY – Expanding Access to Bone-Targeted Therapies Across All Canadian Indications
  • AbbVie’s SKYRIZI (Risankizumab) Secures European Commission Approval for Pediatric Plaque Psoriasis – First IL-23 Inhibitor Authorized for Children as Young as Six
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Company Drug

Takeda Secures NMPA Approval for Adzynma – China’s First Recombinant ADAMTS13 Therapy for Congenital TTP

Company Drug

Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients

Company Drug

Henlius and Organon Canada Launch Denosumab Biosimilars BILDYOS and TUZEMTY – Expanding Access to Bone-Targeted Therapies Across All Canadian Indications

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.